Replies to post #91520 on Avid Bioservices Inc (CDMO)

[golfho]

cjgaddy...

A while back, someone added the market cap value to your share price list. Do you have that? Or, can you direct me to where I can get this information? I'm coming up blank.

Thanks
Golfho

[cjgaddy]

PPHM - O/S Shares History (’06–curr.) – a/o 12-7-12, shares outstanding = 132,539,783, up 28,348,607 since 9-7-12…

4-30-06 35,876,438
1-31-07 39,222,440
4-30-07 39,222,440
7-6-07 45,233,123
7-31-07 45,242,123
10-31-07 45,242,123
1-31-08 45,242,123
4-30-08 45,242,123
7-31-08 45,242,123
10-31-08 45,242,123
1-31-09 45,242,123
4-30-09 45,537,711
7-10-09 47,392,883
7-31-09 47,393,783
10-31-09 48,869,563 +1,475,780
1-31-10 50,903,404 +2,033,841
4-30-10 53,094,894 +2,191,490
6-21-10 54,388,917 +1,294,023 (6-22-10 ATM/mlv Form424)
7-9-10 55,069,449 +475,987 (4-30-10 10K iss. 7-14-10)
7-31-10 55,784,955 +715,506
10-31-10 59,220,742 +3,435,787
11-30-10 63,932,353 +4,711,611 (10-31-10 10Q iss. 12-9-10)
12-15-10 64,404,097 +471,744 (12-17-10 S-3: $75M Shelf Reg.)
1-31-11 66,813,419 +2,409,322
2-28-11 67,885,811 +1,072,392 (1-31-11 10Q iss. 3-11-11)
4-30-11 69,837,142 +1,951,331
7-8-11 71,069,858 +1,232,716 (4-30-11 10K iss. 7-14-11)
8-22-11 72,704,647 +1,634,789 (Proxy iss. 8-26-11)
8-31-11 73,284,016 +579,369 (424B5 iss. 9-2-11)
9-8-11 79,536,268 +6,252,252 (Roth Sale to 3 Inst’s @ $1.11/sh.)
10-31-11 82,638,201 +3,101,933
12-9-11 86,788,817 +4,150,616 (10-31-11 10Q iss. 12-12-11)
1-31-12 93,146,226 +6,357,409
2-29-12 98,873,172 +5,726,946 (1-31-12 10Q iss. 3-9-12)
4-30-12 101,421,365 +2,548,193
7-13-12 104,174,056 +2,752,691 (4-30-12 10K iss. 7-16-12)
7-31-12 104,178,431 +4,375 (7-31-12 10Q iss. 9-10-12)
8-16-12 104,191,176 +12,745 (prelim. proxy 14A http://tinyurl.com/c48bvof )
9-7-12 104,191,176 nochg (7-31-12 10Q iss. 9-10-12)
10-31-12 123,310,188 +19,119,012
12-7-12 132,539,783 +9,229,595 (10-31-12 10Q iss. 12-10-12)

O/S WARRANTS & STOCK-OPTIONS A/O 10-31-2012 (10-Q pg. 12):
…WARRANTS: As of Oct 31, 2012, the following warrants to purchase an aggregate of 493,247 shares of our common stock were outstanding:
• Iss. 12-19-09: 219,967 @ $1.48, exp. 12-19-13
• Iss. 8-30-12: 273,280 @ $2.47, exp. 8-30-18 (Oxford $30mm Loan)
Total Warrants = 493,247 @ avg. exercisable price = $2.03.
...STOCK OPTIONS: 11,631,587 options exercisable & expected to vest, with a wgt.avg. exercise price of $2.06.

= = = = = = = = = = = = = = = = = = = = = = =
• 8-15-12: CEO STEVE KING'S 29MIN. TALK AT WEDBUSH/NYC …SK: "We've laid out our strategy for financing the company; we've not been raising money thru the capital markets in any way. We're not currently planning on going out for, nor have we been actively involved in any other fund-raising activities. Right now, our stated goal is to pursue a debt-arrangement - with an asset like Avid Bioservices, we can get very preferential rates on raising debt-type funding right now, which we feel is the least-dilutive for the company. In fact, our stated goal is to raise $20-30mm thru a debt facility between now and out next earnings call on Sept. 10, 2012. With that capital in the bank, we’ll then will have a 1yr+ runway. We believe that will get us thru the partnering discussions, and then with a partner on board, then certainly we expect that’ll bring in the capital needed to move the company forward for what should hopefully be several years time period. So, that’s our goal – we have a nice, clean cap structure, minimal # of warrants, stock options – there’s no convertible debt on the books, so we think we’re in good shape as we continue to move the company forward into those successful partnering discussions.” http://tinyurl.com/8mhrtld

• CFO PAUL LYTLE, 7-16-12/CC: ”In addition to our focus on growing Avid revenues, our next immediate focus is to secure a less-dilutive debt-financing vehicle, similar to a term loan. Recognizing the growing value in the Avid asset, and the strong clinical data in 2nd-Line NSCLC, we are pursuing a non-convertible-type loan in the range of $20-30mm. We will keep you updated as we get closer to a possible transaction.” ( http://tinyurl.com/cs7spbz )

• 10-31-12 10Q (pg.10): “Subsequently, on Sept. 24, 2012, we received a Notice of Default from the Lenders with respect to the Loan Agreement. The Notice of Default was triggered by a material adverse change under the Loan Agreement due to our discovery of major discrepancies in treatment group coding by an indep. 3rd-party vendor responsible for distribution of blinded investigational product used in our bavituximab Ph2 NSCLC trial... all amounts due under the Loan Agreement were declared immediately due and payable by the Lenders. On 9-25-12, we paid the Lenders all obligations declared due & payable under the Loan Agreement, including o/s principal of $15,000,000, accrued interest thereon at the Loan Agreement’s applicable fixed rate of 7.95% per annum, plus a final payment fee equal to 6.5% of the principal amount funded (or $975,000), upon which, the Loan Agreement was terminated.” http://tinyurl.com/bcoq6yd

• 10-17-12/Corp-Update: “Since 9-27-12, the company has raised $14.3mm in gross proceeds in order to replace the initial funding it repaid under an earlier loan facility. The funds were raised under an At Market Sales Issuance Agreement with MLV at an avg. of $.93/sh. The company issued no warrants in connection with the ATM Agreement. Based on current financial projections for ongoing clinical trials & operations including cash inflows under signed contracts with Avid's existing customers, and assuming the company does not receive addl. proceeds from other potential sources of capital, this funding should provide the company with sufficient capital to reach potential upcoming clinical and development milestones through Q3-CY’13.” http://tinyurl.com/c7gax7y

- - - - - - -
ALL SEC filings for PPHM: http://tinyurl.com/6d4jw8
PPHM's Corp. Bylaws (a/o 12-21-07): http://www.secinfo.com/dV3p8.u4av.d.htm
Poison Pill adopted 3-16-06: http://tinyurl.com/yvypvh - 44-pg SEC filing: http://tinyurl.com/5m57ut